Abstract
Tezepelumab is a human monoclonal antibody that targets thymic stromal lymphopoietin. In the PATHWAY phase 2b study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) and improved lung function in adults with severe, uncontrolled asthma. This post hoc analysis evaluated the efficacy of tezepelumab in patients with allergic and non-allergic asthma grouped according to eligibility for omalizumab (OMA) based on US prescribing information (USPI).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
